Evidence map›Paper›PMID 21129151›Full record

ArticleJournal of cellular and molecular medicine2011

Menin represses malignant phenotypes of melanoma through regulating multiple pathways.

Shu-Bin Gao, Zi-Jie Feng, Bin Xu, Yan Chen, Hong-Hua Zheng, Ping Yin, Xianxin Hua, Guang-Hui Jin

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Menin in Cancer.Genes · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Menin promotes hepatocellular carcinogenesis and epigenetically up-regulates Yap1 transcription.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Shu-Bin GaoDepartment of Basic Medical Sciences, Medical College, Xiamen University, Xiamen, Fujian, China.
Zi-Jie Feng
Bin Xu
Yan Chen
Hong-Hua Zheng
Ping Yin
Xianxin Hua
Guang-Hui Jin
Xiamen University · CNFujian Medical University · CNUniversity of Pennsylvania · USZhongshan Hospital of Xiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Substantial genetic evidence suggests that chromosome 11q is involved in regulating initiation and progression of malignant melanomas. Mutations of the MEN1 gene, located in chromosome 11q13, predispose individuals to the multiple endocrine neoplasia type 1 (MEN1) familial syndrome. MEN1 patients develop primary malignant melanoma, suggesting a potential link between MEN1 syndrome and development of melanomas, but the precise molecular mechanism is poorly understood. Here we show that the MEN1 gene suppresses malignant phenotypes of melanoma cells through multiple signalling pathways. Ectopic expression of menin, the product of MEN1 gene, significantly inhibited melanoma cell proliferation and migration in vitro and in vivo. The inhibition was partly achieved through suppressing expression of growth factor pleiotrophin (PTN) and receptor protein tyrosine phosphatase (RPTP) β/ζ, accompanied with the reduced expression of phosphatidylinositol 3-kinase (pI3K) and decreased phosphorylation of focal adhesion kinase (FAK) and extracellular signal regulated kinase (ERK1/2). Interestingly, reduced expression of menin was associated with hypermethylation of the CpG islands of the MEN1 promoter in melanoma cells. Taken together, these findings suggest a previously unappreciated function for menin in suppressing malignant phenotypes of melanomas and unravel a novel mechanism involving in regulating PTN signalling by menin in development and progression of melanomas.

Indexed as

AnimalsCarrier ProteinsCell Line, TumorCell MovementCell ProliferationChromatin ImmunoprecipitationCpG IslandsCytokinesExtracellular Signal-Regulated MAP KinasesFemaleFocal Adhesion Protein-Tyrosine KinasesHumansIntercellular Signaling Peptides and ProteinsMelanomaMelanoma, ExperimentalMiceCarrier ProteinsCytokinesExtracellular Signal-Regulated MAP KinasesFocal Adhesion Protein-Tyrosine KinasesIntercellular Signaling Peptides and ProteinsMen1 protein, mousePhosphatidylinositol 3-KinasePhosphoinositide-3 Kinase InhibitorspleiotrophinProto-Oncogene ProteinsReceptor-Like Protein Tyrosine Phosphatases, Class 5

Identifiers

PMID21129151
PMCPMC3822947
OpenAlexW2098587743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.